Silexion reports data showing up to 90% inhibition of cancer cell growth

Silexion Therapeutics (SLXN) announced new preclinical data revealing unprecedented inhibition rates of up to 97% in pancreatic cancer cells and almost 90% in colorectal cancer cells. These findings, which include the Company’s first evidence of efficacy against the clinically significant KRAS Q61H mutation in human cancer cells, represent a substantial advancement from previously reported results and further establish SIL204’s potential as a pan-KRAS therapeutic. While the Company has previously reported activity in various cancer models, these latest findings from a comprehensive CTG analysis demonstrate significantly higher inhibition rates and provide the first direct comparison of SIL204’s potency across multiple cancer types and KRAS mutations in a single study, including dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, comparable 97% inhibition in pancreatic cancer cells with the previously untested KRAS Q61H mutation. Key findings from the preclinical studies include: SIL204 demonstrated dose-dependent inhibition of up to 94% in pancreatic cancer cells harboring KRAS G12D mutations at nanomolar concentrations; SIL204 showed comparable efficacy of approximately 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, a variant not previously reported in the Company’s studies; SIL204 produced an inhibition rate of nearly 90% in colorectal cancer cells with KRAS G12D mutations, extending previous evidence of its effectiveness beyond pancreatic cancer. “These findings provide compelling evidence of SIL204’s potent activity against multiple KRAS mutations across different cancer types,” said Ilan Hadar, CEO “The ability to achieve such high levels of inhibition in both pancreatic and colorectal cancer models with different KRAS mutations substantially strengthens SIL204’s potential as a pan-KRAS therapeutic candidate. With these promising results across all three major KRAS-driven cancer types – pancreatic, colorectal, and lung – we’re increasingly confident in SIL204’s potential to address significant unmet needs for patients with these aggressive cancers.”